CliffBio
small molecule

LAMISIL

TERBINAFINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameLAMISIL
Active ingredientTERBINAFINE HYDROCHLORIDE
StrengthEQ 125MG BASE/PACKET
Dosage formGRANULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2007
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.